Key Laboratory of Traditional Chinese Korean Medicine Research (Yanbian University) of State Ethnic Affairs Commission, College of Pharmacy, Yanbian University, Yanji, Jilin Province 133002, China Key ...

Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United States. The FDA has approved Sanofi’s Qfitlia (fitusiran) as the first therapy ...

Agomab Therapeutics NV (?Agomab') today announced that interim data from the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule inhibitor ...

The presentation highlighted tolebrutinib’s potential as the first Bruton's tyrosine kinase (BTK) inhibitor to receive regulatory approval for the treatment of progressive MS. During the ...

The presentation highlighted tolebrutinib’s potential as the first Bruton’s tyrosine kinase (BTK) inhibitor to receive regulatory approval for the treatment of progressive MS. During the Clinical ...

Calcitonin gene-related peptide (CGRP) inhibitors are now considered a first-line treatment used to treat and prevent migraines. There are two types of CGRP medications: monoclonal antibodies and ...

Observational studies and small randomized controlled trials have suggested the benefits of early introduction of sodium–glucose cotransporter 2 inhibitors (SGLT2is) in acute heart failure (AHF).

A once-daily oral PCSK9 inhibitor reduced LDL in patients with hypercholesterolemia. Safety and tolerability profiles were favorable, according to investigators. CHICAGO — In a phase 2b study ...

SGLT2 inhibitors significantly improve hemoglobin and hematocrit levels in CKD patients, enhancing anemia management. The KDIGO 2024 guideline endorses SGLT2 inhibitors for CKD patients ...

Palbociclib, a well-tolerated and selective CDK4/6 inhibitor, has shown promising results in the treatment of retinoblastoma (RB1)-positive breast cancer. RB1 is rarely mutated in HCC, suggesting that ...